Cargando…

Immune Response to COVID-19 mRNA Vaccine—A Pilot Study

Twenty individuals (17 females, 3 males, aged 31–65 years (range), median: 46) who received both doses of the BioNTech Pfizer mRNA vaccine were examined (11 to 31 days, median: 25) after the second dose for the presence of antibodies against peptides of SARS-COV-2 and some of MERS-CoV, SARS-CoV1, HC...

Descripción completa

Detalles Bibliográficos
Autores principales: Lange, Andrzej, Borowik, Agata, Bocheńska, Jolanta, Rossowska, Joanna, Jaskuła, Emilia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150284/
https://www.ncbi.nlm.nih.gov/pubmed/34064613
http://dx.doi.org/10.3390/vaccines9050488
_version_ 1783698115048505344
author Lange, Andrzej
Borowik, Agata
Bocheńska, Jolanta
Rossowska, Joanna
Jaskuła, Emilia
author_facet Lange, Andrzej
Borowik, Agata
Bocheńska, Jolanta
Rossowska, Joanna
Jaskuła, Emilia
author_sort Lange, Andrzej
collection PubMed
description Twenty individuals (17 females, 3 males, aged 31–65 years (range), median: 46) who received both doses of the BioNTech Pfizer mRNA vaccine were examined (11 to 31 days, median: 25) after the second dose for the presence of antibodies against peptides of SARS-COV-2 and some of MERS-CoV, SARS-CoV1, HCov229E, and HCoVNL63. Clinical evaluation revealed that six people had COVID-19 in the past. We found that: (i) Six people claimed the presence of unwanted effects of vaccination, which were more frequent in those with a history of COVID-19 (4 out of 6 vs. 2 out of 14, p = 0.037); (ii) All individuals independent of the past history of COVID-19 responded equally well in IgG but those who experienced the disease tended to do better in IgA class (729.04 vs. 529.78 U/mL, p = 0.079); (iii) All those who had experienced the disease had IgG antibodies against nucleocapsid antigens but also 5 out of 14 who had not had the disease (6/6 vs. 5/14, p = 0.014); (iv) Anti S2 antibodies were present in the patients having COVID-19 in the past but also were found in those who had not had the disease (6/6 vs. 8/14, p = 0.144); (v) All vaccinated people were highly positive in the IGRA and the level of released IFN gamma was correlated with the numbers of HLADR positive lymphocytes in the blood (R = 0.5766, p = 0.008).
format Online
Article
Text
id pubmed-8150284
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81502842021-05-27 Immune Response to COVID-19 mRNA Vaccine—A Pilot Study Lange, Andrzej Borowik, Agata Bocheńska, Jolanta Rossowska, Joanna Jaskuła, Emilia Vaccines (Basel) Communication Twenty individuals (17 females, 3 males, aged 31–65 years (range), median: 46) who received both doses of the BioNTech Pfizer mRNA vaccine were examined (11 to 31 days, median: 25) after the second dose for the presence of antibodies against peptides of SARS-COV-2 and some of MERS-CoV, SARS-CoV1, HCov229E, and HCoVNL63. Clinical evaluation revealed that six people had COVID-19 in the past. We found that: (i) Six people claimed the presence of unwanted effects of vaccination, which were more frequent in those with a history of COVID-19 (4 out of 6 vs. 2 out of 14, p = 0.037); (ii) All individuals independent of the past history of COVID-19 responded equally well in IgG but those who experienced the disease tended to do better in IgA class (729.04 vs. 529.78 U/mL, p = 0.079); (iii) All those who had experienced the disease had IgG antibodies against nucleocapsid antigens but also 5 out of 14 who had not had the disease (6/6 vs. 5/14, p = 0.014); (iv) Anti S2 antibodies were present in the patients having COVID-19 in the past but also were found in those who had not had the disease (6/6 vs. 8/14, p = 0.144); (v) All vaccinated people were highly positive in the IGRA and the level of released IFN gamma was correlated with the numbers of HLADR positive lymphocytes in the blood (R = 0.5766, p = 0.008). MDPI 2021-05-11 /pmc/articles/PMC8150284/ /pubmed/34064613 http://dx.doi.org/10.3390/vaccines9050488 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Lange, Andrzej
Borowik, Agata
Bocheńska, Jolanta
Rossowska, Joanna
Jaskuła, Emilia
Immune Response to COVID-19 mRNA Vaccine—A Pilot Study
title Immune Response to COVID-19 mRNA Vaccine—A Pilot Study
title_full Immune Response to COVID-19 mRNA Vaccine—A Pilot Study
title_fullStr Immune Response to COVID-19 mRNA Vaccine—A Pilot Study
title_full_unstemmed Immune Response to COVID-19 mRNA Vaccine—A Pilot Study
title_short Immune Response to COVID-19 mRNA Vaccine—A Pilot Study
title_sort immune response to covid-19 mrna vaccine—a pilot study
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150284/
https://www.ncbi.nlm.nih.gov/pubmed/34064613
http://dx.doi.org/10.3390/vaccines9050488
work_keys_str_mv AT langeandrzej immuneresponsetocovid19mrnavaccineapilotstudy
AT borowikagata immuneresponsetocovid19mrnavaccineapilotstudy
AT bochenskajolanta immuneresponsetocovid19mrnavaccineapilotstudy
AT rossowskajoanna immuneresponsetocovid19mrnavaccineapilotstudy
AT jaskułaemilia immuneresponsetocovid19mrnavaccineapilotstudy